EP3999496
N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN-2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS)
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
16.7.2020EP published:
18.12.2024EP application number:
20757941.8
EPO information:
European Patent Register
Max expiry date:
15.7.2040
Title in English:
N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-4,5,6,7-TETRAHYDROBENZOFURAN-2-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS NLPR3 MODULATORS FOR THE TREATMENT OF MULTIPLE SCLEROSIS (MS)Language of the patent:
English
Timeline
Today
16.7.2020EP application
18.12.2024EP Publication
Owner
Name:
Zomagen Biosciences LtdAddress:
662 Encinitas Blvd., Suite 250, Encinitas, CA 92024, US
Inventor
Name:
MOHAN, RajuAddress:
Encinitas, CA 92024, US
Name:
NUSS, JohnAddress:
Encinitas, CA 92024, US
Name:
HARRIS, JasonAddress:
Encinitas, CA 92024, US
Name:
YUAN, ShendongAddress:
Encinitas, CA 92024, US
Priority
Number:
201962875402 PDate:
17.7.2019Country:
US
Classification
Categories:
C07D 307/82, C07D 491/04, C07D 333/62, C07C 311/56, A61K 31/343, A61K 31/55, A61K 31/4162, A61P 1/04, A61P 1/16, A61P 3/00, A61P 3/04, A61P 3/10, A61P 9/00, A61P 9/10, A61P 11/00, A61P 11/06, A61P 25/28, A61P 37/00, A61P 37/06